Aurinia Pharmaceuticals Share Price (NASDAQ: AUPH)

$12

▲

-0.08

(-0.66%)

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Aurinia Pharmaceuticals Stock chart to analyse performance

Aurinia Pharmaceuticals stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$11.94
Today's High:$12.15
$12.00
0.5%
Downside
Day's Volatility :1.73%
Upside
1.23%
52 Weeks Low:$6.42
52 Weeks High:$12.53
$12.00
46.5%
Downside
52 Weeks Volatility :48.76%
Upside
4.23%

Aurinia Pharmaceuticals Stock Returns

Period	Aurinia Pharmaceuticals Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	50.69%	3.6%	0.0%
6 Months	50.31%	-7.7%	0.0%
1 Year	79.57%	-12.6%	0.0%
3 Years	64.54%	9.5%	-4.7%

Aurinia Pharmaceuticals Inc Key Stats

Check Aurinia Pharmaceuticals key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$12.08
Open	$12.15
Today's High	$12.15
Today's Low	$11.94
Market Capitalization	$1.6B
Today's Volume	$805.8K
52 Week High	$12.53
52 Week Low	$6.42
Revenue TTM	$260.1M
EBITDA	$82.6M
Earnings Per Share (EPS)	$0.43
PE Ratio	28.09
Profit Margin	23.31%
Quarterly Earnings Growth YOY	30.67%
Return On Equity TTM	17.33%

Stock Returns calculator for Aurinia Pharmaceuticals Stock including INR - Dollar returns

The Aurinia Pharmaceuticals stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Aurinia Pharmaceuticals investment value today

Current value as on today

₹1,81,496

Returns

₹81,496

(+81.5%)

Returns from Aurinia Pharmaceuticals Stock

₹76,211 (+76.21%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Aurinia Pharmaceuticals Stock

300%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Aurinia Pharmaceuticals Stock from India on INDmoney has increased by 300% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Aurinia Pharmaceuticals Inc

Name
Holdings %
Name
Holdings %
TANG CAPITAL MANAGEMENT LLC
7.62%
BlackRock Inc
6.65%
NEA Management Company, LLC
3.02%
State Street Corp
2.17%
Morgan Stanley - Brokerage Accounts
1.80%
Geode Capital Management, LLC
1.32%

Analyst Recommendation on Aurinia Pharmaceuticals Stock

Rating

Trend

Buy

84%Buy

15%Hold

0%Sell

Based on 13 Wall street analysts offering stock ratings for Aurinia Pharmaceuticals(by analysts ranked 0 to 5 stars)

Aurinia Pharmaceuticals Share Price Target

What analysts predicted

Downside of 2.38%

Target:

$11.71

Current:

$12.00

Aurinia Pharmaceuticals share price target is $11.71, a slight Downside of 2.38% compared to current price of $12.00 as per analysts' prediction.

Aurinia Pharmaceuticals Stock Insights

Price Movement
In the last 1 month, AUPH stock has moved up by 32.5%
Increasing Revenue
Revenue is up for the last 3 quarters, 59.86M → 70.00M (in $), with an average increase of 7.5% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, 23.34M → 21.51M (in $), with an average decrease of 7.8% per quarter
AUPH vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 112.6% return, outperforming this stock by 52.9%

Aurinia Pharmaceuticals Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$318.0K	↓ 31.32%
Net Income	$-123.8M	↑ 93.15%
Net Profit Margin	-38.9K%	↓ 25096.47%

	FY20	Y/Y Change
Revenue	$50.1M	↑ 15660.38%
Net Income	$-102.7M	↓ 17.09%
Net Profit Margin	-204.88%	↑ 38740.4%

	FY21	Y/Y Change
Revenue	$45.6M	↓ 9.0%
Net Income	$-181.0M	↑ 76.24%
Net Profit Margin	-396.81%	↓ 191.93%

	FY22	Y/Y Change
Revenue	$134.0M	↑ 193.89%
Net Income	$-108.2M	↓ 40.22%
Net Profit Margin	-80.71%	↑ 316.1%

	FY23	Y/Y Change
Revenue	$175.5M	↑ 30.95%
Net Income	$-78.0M	↓ 27.88%
Net Profit Margin	-44.45%	↑ 36.26%

	FY24	Y/Y Change
Revenue	$235.1M	↑ 33.97%
Net Income	$5.8M	↓ 107.37%
Net Profit Margin	2.45%	↑ 46.9%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$50.3M	↑ 11.55%
Net Income	$-10.7M	↓ 60.0%
Net Profit Margin	-21.37%	↑ 38.23%

	Q2 FY24	Q/Q Change
Revenue	$57.2M	↑ 13.7%
Net Income	$722.0K	↓ 106.72%
Net Profit Margin	1.26%	↑ 22.63%

	Q3 FY24	Q/Q Change
Revenue	$67.8M	↑ 18.5%
Net Income	$14.4M	↑ 1887.53%
Net Profit Margin	21.17%	↑ 19.91%

	Q4 FY24	Q/Q Change
Revenue	$59.9M	↓ 11.66%
Net Income	$1.4M	↓ 90.04%
Net Profit Margin	2.39%	↓ 18.78%

	Q1 FY25	Q/Q Change
Revenue	$62.5M	↑ 4.34%
Net Income	$23.3M	↑ 1533.59%
Net Profit Margin	37.37%	↑ 34.98%

	Q2 FY25	Q/Q Change
Revenue	$70.0M	↑ 12.08%
Net Income	$21.5M	↓ 7.84%
Net Profit Margin	30.73%	↓ 6.64%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$-52.5M	↑ 28.42%

	FY20	Y/Y Change
Profit	$-209.0K	↓ 99.6%

	FY21	Y/Y Change
Profit	$44.5M	↓ 21398.56%

	FY22	Y/Y Change
Profit	$128.4M	↑ 188.37%

	FY23	Y/Y Change
Profit	$161.4M	↑ 25.71%

	FY24	Y/Y Change
Profit	$206.9M	↑ 28.21%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$42.6M	↑ 7.18%

	Q2 FY24	Q/Q Change
Profit	$48.3M	↑ 13.47%

	Q3 FY24	Q/Q Change
Profit	$61.7M	↑ 27.86%

	Q4 FY24	Q/Q Change
Profit	$54.3M	↓ 12.02%

	Q1 FY25	Q/Q Change
Profit	$53.9M	↓ 0.78%

	Q2 FY25	Q/Q Change
Profit	$62.9M	↑ 16.7%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-63.5M	↑ 22.95%
Investing Cash Flow	$7.8M	↓ 11887.88%
Financing Cash Flow	$243.7M	↑ 5971.95%

	FY20	Y/Y Change
Operating Cash Flow	$-69.9M	↑ 10.09%
Investing Cash Flow	$-158.2M	↓ 2133.24%
Financing Cash Flow	$194.4M	↓ 20.25%

	FY21	Y/Y Change
Operating Cash Flow	$-157.7M	↑ 125.73%
Investing Cash Flow	$-103.9M	↓ 34.34%
Financing Cash Flow	$221.1M	↑ 13.76%

	FY22	Y/Y Change
Operating Cash Flow	$-79.5M	↓ 49.57%
Investing Cash Flow	$-60.6M	↓ 41.63%
Financing Cash Flow	$2.4M	↓ 98.9%

	FY23	Y/Y Change
Operating Cash Flow	$-33.5M	↓ 57.93%
Investing Cash Flow	$-6.7M	↓ 88.94%
Financing Cash Flow	$-5.1M	↓ 310.85%

	FY24	Y/Y Change
Operating Cash Flow	$44.4M	↓ 232.66%
Investing Cash Flow	$39.3M	↓ 685.48%
Financing Cash Flow	$-49.1M	↑ 856.96%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-18.6M	↓ 225.53%
Investing Cash Flow	$49.2M	-
Financing Cash Flow	$-15.1M	↑ 172.05%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$15.9M	↓ 185.29%
Investing Cash Flow	$-38.7M	↓ 178.6%
Financing Cash Flow	$-8.1M	↓ 46.13%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$17.0M	↑ 7.35%
Investing Cash Flow	$-10.6M	↓ 72.68%
Financing Cash Flow	$-2.7M	↓ 66.43%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$30.1M	↑ 76.84%
Investing Cash Flow	$39.2M	↓ 471.01%
Financing Cash Flow	$-23.0M	↑ 746.66%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$1.3M	↓ 95.68%
Investing Cash Flow	$31.0M	↓ 20.88%
Financing Cash Flow	$-49.3M	↑ 114.08%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$44.2M	↑ 3303.15%
Investing Cash Flow	$-13.3M	↓ 142.77%
Financing Cash Flow	$-44.4M	↓ 10.02%

Aurinia Pharmaceuticals Technicals Summary

Sell

Neutral

Buy

Aurinia Pharmaceuticals is currently in a neutral trading position according to technical analysis indicators.

Aurinia Pharmaceuticals Inc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Aurinia Pharmaceuticals Inc	29.75%	50.31%	79.57%	64.54%	-17.5%
Regeneron Pharmaceuticals, Inc.	6.48%	-15.2%	-50.31%	-3.3%	-2.01%
Beone Medicines Ltd	1.77%	24.81%	62.78%	79.11%	29.69%
Vertex Pharmaceuticals Incorporated	-14.45%	-19.13%	-17.84%	34.68%	41.87%
Alnylam Pharmaceuticals, Inc.	13.79%	83.28%	75.87%	111.28%	242.25%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Aurinia Pharmaceuticals Inc	28.09	28.09	0.0	0.65	0.17	0.08	NA	2.53
Regeneron Pharmaceuticals, Inc.	14.6	14.6	1.2	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.73	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.86	27.86	0.58	18.06	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Aurinia Pharmaceuticals Inc	Buy	$1.6B	-17.5%	28.09	23.31%
Regeneron Pharmaceuticals, Inc.	Buy	$61.4B	-2.01%	14.6	31.37%
Beone Medicines Ltd	NA	$36.5B	29.69%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$100.5B	41.87%	27.86	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$59.5B	242.25%	NA	-12.96%

About Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs. It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Organization	Aurinia Pharmaceuticals
Employees	130
CEO	Mr. Peter S. Greenleaf M.B.A.
Industry	Health Technology

Key Management of Aurinia Pharmaceuticals Inc

Name	Title
Mr. Peter S. Greenleaf M.B.A.	President, CEO & Director
Mr. Joseph M. Miller CPA	Chief Financial Officer
Mr. Matthew Maxwell Donley M.B.A.	Chief Operations Officer
Mr. Stephen P. Robertson	Executive VP, General Counsel, Corporate Secretary & Chief Compliance Officer
Dr. Gregory F. Keenan M.D.	Chief Medical Officer
Ms. Andrea Levin Christopher	Executive Director of Corporate Communications & Investor Relations
Dr. Premchandran Ramiya Ph.D.	Senior Vice President of Manufacturing & Supply Chain

Important FAQs about investing in AUPH Stock from India :

What is Aurinia Pharmaceuticals share price today?

Aurinia Pharmaceuticals share price today is $12.00 as on August 30, 2025 at 1:29 am IST at the close of the market. Aurinia Pharmaceuticals share today touched a day high of $12.15 and a low of $11.94.

What is the 52 week high and 52 week low for Aurinia Pharmaceuticals share?

Aurinia Pharmaceuticals share touched a 52 week high of $12.53 and a 52 week low of $6.42. Aurinia Pharmaceuticals stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $12.00, lower by 4.23% versus the 52 week high.

How to invest in Aurinia Pharmaceuticals Stock (AUPH) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Aurinia Pharmaceuticals on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Aurinia Pharmaceuticals Shares that will get you 0.1250 shares as per Aurinia Pharmaceuticals share price of $12.00 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Aurinia Pharmaceuticals Stock (AUPH) from India?

Indian investors can start investing in Aurinia Pharmaceuticals (AUPH) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Aurinia Pharmaceuticals stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Aurinia Pharmaceuticals share’s latest price of $12.00 as on August 30, 2025 at 1:29 am IST, you will get 0.8333 shares of Aurinia Pharmaceuticals. Learn more about fractional shares .

What are the returns that Aurinia Pharmaceuticals has given to Indian investors in the last 5 years?

Aurinia Pharmaceuticals stock has given -17.5% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?